The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 peptide Nanox 5 mg 5 vials BPC 157 Sovereign Health Performance Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law FDA Peptide Update: Category 2 Removals Explained FDA to Review 7 Peptides for Compounding List in July 2026: BPC 157, Semax, Epitalon, and More HealingMaps